Examkin

Soru

Zorluk: OrtaPharmacologic Interventions

A 54-year-old man is evaluated in the intensive care unit for new-onset right lower extremity swelling and pain. He was admitted six days ago for an acute right-sided pulmonary embolism and was subsequently started on a continuous unfractionated heparin infusion. His initial recovery was uncomplicated. Today, physical examination reveals a swollen, erythematous, and tender right calf. His vital signs are temperature 37.1°C (98.8°F), blood pressure 128/82 mmHg, and heart rate 88/min.

Recent laboratory studies are as follows:

Laboratory TestResultReference Range
Hemoglobin13.2 g/dL13.5-17.5 g/dL (male)
Platelet count, today85,000/mm³150,000-400,000/mm³
Platelet count, admission260,000/mm³150,000-400,000/mm³
Serum creatinine1.0 mg/dL0.6-1.2 mg/dL

A lower extremity venous Doppler ultrasound confirms an acute occlusive deep vein thrombosis in the right popliteal vein. Which of the following is the most appropriate next step in the pharmacologic management of this patient?

  1. A
    Discontinue unfractionated heparin and initiate enoxaparin
  2. B
    Discontinue unfractionated heparin and initiate warfarin
  3. Discontinue unfractionated heparin and initiate an argatroban infusionCevap
  4. D
    Continue unfractionated heparin and order a serotonin release assay
  5. E
    Discontinue unfractionated heparin and transfuse pooled platelets

Cevap

The most appropriate intervention is to discontinue the unfractionated heparin and initiate an argatroban infusion.
The clinical presentation is highly suggestive of Heparin-Induced Thrombocytopenia (HIT) Type 2. This condition is characterized by a platelet count drop of >50%, typically occurring 5-10 days after heparin initiation, and is paradoxically highly prothrombotic, often complicated by new events like a deep vein thrombosis. The standard of care requires the immediate cessation of all heparin products and the initiation of a non-heparin anticoagulant. Argatroban, a direct thrombin inhibitor, is an appropriate choice to provide immediate anticoagulation and prevent further thrombosis while the diagnosis is confirmed.

Adım Adım Çözüm

1
Evaluate the patient's acute thrombocytopenia and new thrombosis in the context of recent medication exposure.
The timing (day 6 of therapy) and severity (>50% drop) of the thrombocytopenia, combined with a new thrombosis, yield a high 4T score strongly pointing to Heparin-Induced Thrombocytopenia (HIT) Type 2.
Calculating a 4T score is essential to estimate the pretest probability of HIT before taking interventional steps.
2
Determine the immediate pharmacologic intervention required for suspected HIT.
All heparin-containing products must be discontinued immediately without waiting for confirmatory laboratory testing.
Heparin-PF4 autoantibodies drive the pathogenesis, so removing the trigger is the critical first step in stabilization.
3
Select a safe alternative anticoagulant to treat the new deep vein thrombosis and underlying pulmonary embolism.
Initiate a non-heparin anticoagulant, such as a direct thrombin inhibitor (argatroban).
Patients with HIT are highly prothrombotic and require immediate alternative anticoagulation that does not cross-react with HIT autoantibodies.

Anahtar Kavram

Management of Heparin-Induced Thrombocytopenia (HIT)
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru